The role of aspirin for stroke prevention in atrial fibrillation

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Atrial fibrillation (AF) significantly increases the risk of stroke and thromboembolism, leading to considerable patient morbidity and mortality.
• Aspirin monotherapy is often insufficient for effective stroke prevention in most AF patients, showing inferiority to warfarin, particularly in elderly populations.
• Emerging novel oral anticoagulants (NOACs) further challenge the established role of aspirin in AF stroke prevention.

Approach:

• This analysis reviews the current evidence regarding aspirin's efficacy and safety in stroke prevention for patients with atrial fibrillation.
• It considers the role of aspirin in conjunction with other antithrombotic agents in specific clinical scenarios.
• The review also evaluates alternative antithrombotic strategies, including NOACs and dual antiplatelet therapy.

Key Points:

• Aspirin is generally less effective and not necessarily safer than warfarin for long-term stroke prevention in AF.
• Novel oral anticoagulants offer alternative and potentially more effective stroke prevention strategies for AF patients.
• Aspirin, often combined with clopidogrel, may be considered in specific short-term settings, such as acute coronary syndrome or post-stenting, or for patients unable to use oral anticoagulants due to monitoring difficulties or bleeding risk concerns.

Conclusions:

• For the majority of patients with atrial fibrillation, aspirin is not the preferred agent for stroke prevention.
• Warfarin and novel oral anticoagulants represent more effective strategies for reducing stroke risk in AF.
• Aspirin's role is limited to specific short-term indications or in select patient groups who cannot adhere to or tolerate oral anticoagulation therapy.